Tango Therapeutics financials
$24.42+0.49%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $53.8M | $3.2M | $5.4M | $4.1M | $11.6M | $19.9M | $6.5M | $5.4M | $10.7M |
| Gross profit | $0.00 | $0.00 | $0.00 | $53.8M | $3.2M | $5.4M | $4.1M | $11.6M | $19.9M | $6.5M | $5.4M | $10.7M |
| Gross margin | — | — | — | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | -$59.8M | -$48.8M | -$41.9M | $14.1M | -$41.0M | -$42.5M | -$40.9M | -$32.9M | -$29.6M | -$42.3M | -$35.0M | -$25.6M |
| Net income | -$55.3M | -$45.5M | -$38.7M | $15.9M | -$38.9M | -$39.9M | -$37.7M | -$29.2M | -$25.6M | -$37.9M | -$30.8M | -$22.3M |
| Net margin | — | — | — | 29.5% | −1221.4% | −739.5% | −915.0% | −251.3% | −128.6% | −585.9% | −566.4% | −207.4% |
| Diluted EPS | $-0.37 | $-0.32 | $-0.31 | $0.13 | $-0.35 | $-0.36 | $-0.34 | $-0.27 | $-0.24 | $-0.35 | $-0.29 | $-0.23 |
| EBITDA | -$59.4M | -$48.3M | -$41.4M | $14.6M | -$40.3M | -$41.9M | -$40.3M | -$32.3M | -$28.9M | -$41.6M | -$35.0M | -$25.0M |
| Operating cash flow | -$38.9M | -$44.4M | -$29.7M | -$31.0M | -$36.5M | -$41.7M | -$36.6M | -$33.4M | -$23.6M | -$37.9M | -$27.5M | -$31.1M |
| Free cash flow | -$38.9M | -$44.4M | -$29.9M | -$31.1M | -$37.1M | -$41.7M | -$36.8M | -$33.5M | -$23.9M | -$38.1M | -$27.7M | -$31.2M |
| Diluted shares | 149.9M | 143.6M | 126.0M | 117.8M | 110.5M | 110.3M | 111.9M | 108.5M | 108.3M | 108.2M | 104.7M | 97.0M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $345.6M | $157.8M | $112.3M | $58.3M | $39.3M | $58.4M |
| Short-term investments | $668.4M | $222.0M | $230.9M | $94.5M | $141.5M | $158.3M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $1.07B | $435.8M | $398.7M | $210.1M | $237.9M | $274.3M |
| Total liabilities | $49.3M | $44.3M | $52.5M | $50.1M | $102.9M | $107.5M |
| Shareholders' equity | $1.02B | $391.5M | $346.2M | $160.0M | $135.0M | $166.8M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology